Alexander L. Weis
Amministratore Delegato presso ONCOVISTA INNOVATIVE THERAPIES, INC.
Profilo
Alexander L.
Weis was the founder of ILEX Oncology, Inc. (founded in 1994) where he served as the Chief Scientific Officer & Executive VP from 1994 to 1998.
He was also the founder of Lipitek International, Inc. (founded in 1989) where he was the President from 1989 to 2004.
Additionally, he is the founder of OncoVista-Sub (founded in 2004) and currently holds the position of Chairman, President & Chief Executive Officer.
Dr. Weis's current job(s) include being the Chairman-Supervisory Board & CEO at Alere Diagnostics GmbH since 2009 and the President, CEO, CFO & Chief Accounting Officer at OncoVista Innovative Therapies, Inc. since 2007.
His former job(s) include being the Chief Executive Officer at Aviation Upgrade Technologies, Inc., the President & Chief Executive Officer at OncoVista, Inc., and holding positions at Eastman Kodak Co., Sterling Drug, Inc., and Weizmann Institute of Science.
Dr. Weis obtained a doctorate degree from N.N.
Vorozhtsov Novosibirsk Institute of Organic Chemistry.
Posizioni attive di Alexander L. Weis
| Società | Posizione | Inizio |
|---|---|---|
| ONCOVISTA INNOVATIVE THERAPIES, INC. | Amministratore Delegato | 16/08/2007 |
Alere Diagnostics GmbH
 Alere Diagnostics GmbH Medical SpecialtiesHealth Technology Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany. | Amministratore Delegato | 01/02/2009 |
| OncoVista-Sub | Amministratore Delegato | - |
Precedenti posizioni note di Alexander L. Weis
| Società | Posizione | Fine |
|---|---|---|
| Aviation Upgrade Technologies, Inc. | Presidente | 14/01/2008 |
OncoVista, Inc.
 OncoVista, Inc. Electronic Equipment/InstrumentsElectronic Technology OncoVista, Inc. develops cancer treatment technology. The firm provides drug discovery technologies, clinical development and registration strategies solutions. The company was founded in 2004 and is located in San Antonio, TX. | Presidente | 14/01/2008 |
| Lipitek International, Inc. | Fondatore | 01/09/2004 |
ILEX Oncology, Inc.
 ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Fondatore | 01/01/1998 |
| Sterling Drug, Inc. | Corporate Officer/Principal | - |
Formazione di Alexander L. Weis
| N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| EASTMAN KODAK COMPANY | Producer Manufacturing |
| ONCOVISTA INNOVATIVE THERAPIES, INC. | Health Technology |
| Aziende private | 7 |
|---|---|
Alere Diagnostics GmbH
Alere Diagnostics GmbH Medical SpecialtiesHealth Technology Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany. | Health Technology |
| Aviation Upgrade Technologies, Inc. | Producer Manufacturing |
OncoVista, Inc.
OncoVista, Inc. Electronic Equipment/InstrumentsElectronic Technology OncoVista, Inc. develops cancer treatment technology. The firm provides drug discovery technologies, clinical development and registration strategies solutions. The company was founded in 2004 and is located in San Antonio, TX. | Electronic Technology |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Health Technology |
| Sterling Drug, Inc. | Consumer Non-Durables |
| Lipitek International, Inc. | |
| OncoVista-Sub |
- Borsa valori
- Insiders
- Alexander L. Weis
